Nanfang Hospital, Southern Medical University: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Nanfang Hospital, Southern Medical University as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 8Phase 3 7Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALLRecruitingNCT07203352Phase 3
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
- Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
- Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplantsStatus unknownNCT03624530Phase 2/3
- Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLStatus unknownNCT03564704Phase 2/3
- Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Phase 2/3
- Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALLStatus unknownNCT03553238Phase 2/3
- Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT03331211
- BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCTCompletedNCT02670252Phase 3
- TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaStatus unknownNCT01883219Phase 2
- HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALLStatus unknownNCT01873807Phase 4
- Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic LeukemiaCompletedNCT01457040Phase 2/3